US 4886741

I'll run searches to check for USPTO records and any CAFC 2026 docket activity for this specific patent number.

Search scope and result

I searched for the literal identifier 4886741 / US 4,886,741 against patent databases (Google Patents, PubChem patent record, Justia, USPTO.report, Unified Patents portal) and against Federal Circuit 2026 docket material (Fed. Cir. opinions, IPWatchdog, Gibson Dunn Fed. Cir. updates, USPTO Director orders referencing Fed. Cir. appeal numbers). No Federal Circuit 2026 appeal, IPR/PGR appeal, or district-court case involving this patent number surfaced. That is consistent with the record: the patent is listed as Expired – Lifetime, anticipated expiration 2007-12-09, so ~18 years before the current date, making 2026 appellate activity implausible. I found no basis to assert any 2026 litigation. I did not have direct access to a USPTO PatentCenter/CAFC PACER query interface in this session, so treat the "no litigation found" statement as based on open-web records only, not an exhaustive docket search.

Bibliographic summary (US 4,886,741)

Abstract (verbatim from the patent): "This invention relates to methods for using volume exclusion agents to enhance in situ hybridization rates between short oligonucleotide probes and their target polynucleotides where the cells containing the target polynucleotides are adhered onto a glass substrate. In one aspect, the invention specifically relates to the use of volume exclusion agents to facilitate assay and diagnostic procedures for the detection of a virus, such as human papillomavirus (HPV). In addition, diagnostic kits embracing the above methods are described herein."

Independent claims — plain language

The patent has 12 claims, of which claims 1 and 10 are independent.

Claim 1 — in situ detection method. A method for detecting target polynucleotides inside cells, in four steps:

• (a) fix the cells onto an inert, transparent, solid support (e.g., a glass slide);
• (b) apply a hybridization mixture containing (i) labeled short probes of 15–30 nucleotides that can hybridize to the target, and (ii) a volume exclusion agent at 2%–25% w/v of the mixture;
• (c) wash unbound probes off the support — with the express requirement that steps (b) and (c) together take 4 hours or less;
• (d) detect the labeled probes that hybridized to the cells, where detecting the probe is correlated with detecting the target polynucleotide.

The practical thrust: the inventors claim that adding a volume-excluding polymer lets a short (oligonucleotide) probe complete hybridization and washing within a ~4-hour clinical-turnaround window, contrary to the then-prevailing view (discussed in the specification citing Meinkoth & Wahl, Anal. Biochem. 138:267–284) that dextran sulfate gave no benefit for probes as short as ~14 bases and that ~400-nucleotide probes were optimal for in situ work.

Claim 10 — diagnostic kit. A kit for in situ detection of target polynucleotides by hybridization-and-wash methodology where those steps are completed in four hours or less, comprising:

• (a) fixation reagents for fixing cells to an inert support; and
• (b) hybridization reagents including an in situ hybridization reaction mixture with labeled 15–30-nucleotide short probes plus a volume exclusion agent at 2–25% of the mixture, where the mixture is characterized as producing detectable hybridization in about a one-hour hybridization period.

Dependent claims (brief)

• Claim 2: volume exclusion agent is polyethylene glycol (PEG) or an anionic polymer selected from polyacrylate, polymethylacrylate, and polysaccharidic polymers.
• Claim 3: the polysaccharidic polymer is dextran sulfate at 5%–20%.
• Claim 4: the probe binds targets arising from human papillomavirus (HPV) infection.
• Claim 5 / 6 / 7: probes are biotinylated; or directly conjugated to an enzyme; the enzyme being alkaline phosphatase.
• Claim 8: HPV isolates from cervical or anogenital-region cells.
• Claim 9: the support is glass.
• Claim 11 / 12: kit-side counterparts of claims 2 and 3 (anionic polymer; dextran sulfate at 5%–20%).

Points of uncertainty / discrepancies to flag

1. "15–50" vs. "15–30" nucleotides. The specification and the abstract material repeatedly describe "short probes" as 15 to 50 nucleotides, and the granted claim 1 recites 15 and 30 nucleotides (per the Google Patents claim text: "labeled short probes or between 15 and 30 nucleotides," where "or" is almost certainly OCR of "of"). The WO 89/05357 amended version of claim 1 reads "about 15 to about 50," with a separate dependent claim reciting ≥15 and ≤30. So the issued U.S. claim scope (15–30) differs from the PCT amended claim (≈15–50). I am reporting the issued U.S. claim text as authoritative for the U.S. patent.
2. Date discrepancies across secondary databases. Google Patents and PubChem give priority/filing 1987-12-09 and grant 1989-12-12; the Unified Patents portal lists priority 1987-12-08, grant 1989-12-11, expiration 2007-12-08. The differences are likely time-zone/derivation artifacts. I have used the values in the authoritative full text (1987-12-09 filing; 1989-12-12 issue; 2007-12-09 anticipated expiration).
3. Examiner name (Robert J. Warden, with Jack Spiegel listed) comes from a secondary aggregator (Unified Patents) and I cannot independently verify it from the authoritative text.
4. Related applications cited in the specification. The patent incorporates by reference U.S. Pat. No. 4,689,294 (polyacrylate/polymethylacrylate hybridization accelerators), U.S. Pat. No. 4,302,204 (Wahl & Stark, volume exclusion — cited in the Information Disclosure discussion), WO 86/05816 (HPV L1 genus/type-specific regions), and U.S. Ser. No. 130,754 (ultrasound-enhanced hybridization, filed the same day, 1987-12-09). Also noted: U.S. application Ser. No. 103,979 filed 1987-10-02, "Human Papillomavirus Type Diagnosis With Nucleotide Probes" (the patent text spells it "Nucelotide").
5. Assignee history nuance: MicroProbe Corporation is the original assignee; the 1996-01-16 assignment to Becton, Dickinson and Company is what Google Patents shows as the current assignee. I found no 2026 CAFC or PTAB activity for this number.

I'll research litigation involving US Patent 4,886,741. Let me search multiple litigation databases.

Let me search litigation-specific databases and case law sources.

Let me check litigation-specific patent databases with targeted searches.

Litigation Search: U.S. Patent No. 4,886,741

Patent identified: U.S. Patent No. 4,886,741 — "Use of volume exclusion agents for the enhancement of in situ hybridization." Application No. 07/130,709; filed December 9, 1987; granted December 12, 1989; inventor Dennis E. Schwartz; original assignee MicroProbe Corporation (later assigned to Becton, Dickinson and Company). Anticipated expiration December 9, 2007 (status: Expired – Lifetime).

Finding: No litigation located

Based on my searches, I found no record of any litigation involving U.S. Patent 4,886,741. Specifically:

• No district court infringement action, declaratory judgment action, or ANDA/Paragraph IV action naming the '741 patent as an asserted patent appeared in any of the sources searched.
• No PTAB proceeding (IPR/PGR/CBM) referencing the '741 patent was found.
• No CAFC appeal referencing the '741 patent was found.

The Unified Patents patent portal entry for US-4886741-A (https://portal.unifiedpatents.com/patents/patent/US-4886741-A) — which incorporates litigation data for listed patents — surfaced only bibliographic and patentability data (parent company Becton Dickinson and Co.; original assignee MicroProbe Corp). It did not surface any associated litigation records. Likewise, the Google Patents page (https://patents.google.com/patent/[US4886741](/patent/US4886741)/en) lists patent family members (WO1989005357A1 and AU2913789A) and 77 forward citations, but no litigation or "Litigation" section.

Case list

Important caveats — please weigh these before relying on the absence of litigation

1. I could not directly query PACER or the CAFC docket system, as those require authenticated/paid access that wasn't available to me. My search relied on public web indexes and patent-analytics portals. A PACER docket search on "4,886,741" and on the likely plaintiffs (MicroProbe Corporation; Becton, Dickinson and Company) would be the definitive check and should be run before concluding no litigation exists.
2. Several search results contained the digit string "4886741" but are unrelated false positives and must not be mistaken for this patent. For example, a UK Gazette notice referencing company number 06884748; a Brazilian JUCISRS registration list; a Lithuanian registry entry; and a completely different patent, U.S. Patent No. 12,042,741 (the "'741 Patent" referred to in an unrelated 2024 Amazon-takedown case, D. Del. or W.D. Wash. matter). I have excluded all of these.
3. No auto-correction was applied. The number you supplied, 4886741, matches U.S. Patent No. 4,886,741 exactly as issued.
4. Practical/chronological context (not evidence of litigation, but relevant to likelihood): this is a 1989-issued biotechnology patent that expired in December 2007. Its owner, MicroProbe Corporation, was acquired by Becton, Dickinson and Company in 1996. Any enforcement activity would necessarily have predated the 2007 expiration, yet none is indexed.
5. Absence of evidence is not proof of absence. Some 1980s–1990s biotech enforcement actions were resolved by settlement and are poorly indexed in modern analytics databases; a case that settled early or was voluntarily dismissed pre-2000 may not appear.

Recommendation

To confirm this negative finding with direct authority, I recommend running:

• A PACER "Case Number" / "Party" search in the relevant districts (notably W.D. Wash., where MicroProbe was located in Bothell, WA, and D. Del./D.N.J., common venues for biotech),
• A CAFC docket search,
• A USPTO Patent Assignment / litigation-history check, and
• A Lex Machina / Docket Navigator query on patent number 4,886,741.

If you'd like, I can draft the specific queries for those databases, or search again once you confirm which jurisdictions and date ranges you want covered.

I'll verify the structured data against public sources before writing up.

PTAB / AIA Trial Analysis — US 4,886,741

Bottom line up front: there are no AIA trial proceedings on this patent, and there could not have been. The USPTO ODP structured block returns an empty PTAB proceedings list, and my web checks surfaced no IPR, PGR, or CBM involving US 4,886,741 — not even an institution denial. The reason is chronological, not strategic: the patent lapsed before the AIA trial regime existed.

Proceedings overview

Total proceedings on file: 0. No active proceedings, no invalidated claims, no sustained claims, no settlements, no institution denials — because AIA trials are unavailable for this patent.

The defensive posture this gives a defendant is not "the patent survived and is hardened" and not "claims 1–5 were canceled." It is stronger and simpler: the patent expired on or about 2007-12-09, roughly five years before the first IPR petition was ever filed (2012-09-16). Every claim 1–12 is expired, unenforceable, and incapable of supporting an infringement claim today. If a demand letter cites US 4,886,741 as a basis for liability on current activity, that letter is meritless on its face. The only theoretical exposure would be for acts committed before expiration — and the six-year damages lookback under 35 U.S.C. § 286 closed that window around 2013.

Confidence note: high on the "no AIA proceedings" conclusion (structured ODP data plus multiple independent web checks). Medium-high on the exact expiry date — see the date discrepancy flagged below.

Proceeding-by-proceeding

None to report. No proceeding numbers exist to populate this section, and I will not manufacture placeholders. Below is the structural explanation for why the section is empty, which is what a defendant actually needs.

Why US 4,886,741 was never IPR-able

• Type: N/A — AIA trials (IPR/PGR/CBM) were unavailable during the patent's enforceable life.
• Filed: N/A.
• Status: Patent status per Google Patents: "Expired - Lifetime", with "Anticipated expiration 2007-12-09." (Google Patents)
• Statutory gate — IPR: 35 U.S.C. §§ 311–319 IPRs became available only for petitions filed on or after 2012-09-16. This patent's term ended in 2007. There was no window in which an IPR could be filed against a live patent.
• Statutory gate — PGR: PGR under 35 U.S.C. §§ 321–329 applies only to patents with an effective filing date on or after 2013-03-16. This application was filed 1987-12-09. Categorically ineligible.
• Statutory gate — CBM: CBM review under AIA § 18 was limited to patents claiming a "financial product or service." This patent claims an in situ nucleic-acid hybridization method (CPC C12Q1/6841, C12Q1/6832, C12Q1/708). Categorically outside CBM subject matter.
• Pre-AIA alternatives checked: Ex parte reexamination (available since 1981) and inter partes reexamination (1999–2012) were the only post-grant options during this patent's life. My searches surfaced no evidence of either. I could not exhaustively confirm this because the application file wrapper (Application No. 07/130,709) was not directly queryable in this session — see Recommended next steps.
• Prosecution/post-grant history on record: Filed 1987-12-09 by MicroProbe Corp.; inventor Dennis E. Schwartz; assigned to MicroProbe Corporation 1988-02-16; granted 1989-12-12; assigned to Becton, Dickinson and Company 1996-01-16; anticipated expiration 2007-12-09. Family members: WO1989005357A1 and AU29137/89A, both filed 1988-12-06 off the same 1987-12-09 priority — also long expired.
• Litigation on record: I found no reported infringement action asserting this patent. The contemporaneous HPV-probe litigation I did find (Digene v. Ventana/Beckman, and Digene's HPV-probe patents) involved different patents — the '331/'332 Digene HPV 35/44 patents — not the '741. MicroProbe's 1993–94 dispute with Gen-Probe involved U.S. Patent 4,851,330 and MicroProbe's Affirm VP product line, again not the '741.
• Appeal: None. No PTAB FWD exists, so no Federal Circuit appeal from one exists. Nothing on the Federal Circuit docket or CourtListener for this patent number.
• Defensive value: Total. The patent is a historical citation, not an assertion asset. Today the '741 is cited as background prior art by later filers (e.g., it appears in the reference lists of EP 3,597,740 A1 and EP 2,620,510 B1) — that is the only role it plays in modern prosecution.

Strategic summary

Claim status. All twelve claims (1–12) of US 4,886,741 lapsed at end of term. None were canceled in an AIA trial, and none were held unpatentable — because no such trial ever occurred. Do not let an adversary's framing ("the claims have never been invalidated") obscure the operative fact: expired claims are UNTESTED in the PTAB sense but UNENFORCEABLE in the practical sense. There is no surviving claim set to infringe. Claim 1 (the method claim reciting fixation, a 15–30 nucleotide labeled short probe, 2–25% w/v volume exclusion agent, and completion of hybridization plus washing in ≤4 hours) and independent claim 10 (the corresponding kit claim) are both dead — the kit claim is worth noting because expired kit claims are occasionally recycled in demand letters against reagent vendors' packaging, and this one cannot support a suit.

Date discrepancy to reconcile before relying on the deadline math. Google Patents states anticipated expiration 2007-12-09 (20 years from the 1987-12-09 filing date, which under the URAA transitional rules exceeds the 17-years-from-grant date of 2006-12-12). Unified Patents' portal lists 2007-12-08 for both priority and expiration, and lists the grant date as 1989-12-11 rather than 1989-12-12 (Unified Patents). These are one-day discrepancies, immaterial to any defensive analysis, but I am reporting them rather than silently picking one. Unified also reports "Lifetime Renewal Fees: $0," which, if accurate as a maintenance-fee record rather than a data artifact, could mean the patent went abandoned earlier than its nominal term. I could not verify this against the USPTO fee record, so treat 2007-12-09 as the outside date (the latest possible expiration) — which makes the defensive conclusion conservative and therefore safe.

Estoppel landscape. Section 315(e)(2) estoppel is irrelevant here: no petitioner ever filed an IPR, so no petitioner is estopped from anything, and no prior-art ground has ever been adjudicated. That cuts both ways. A defendant gains no benefit from a prior petitioner's work — there is no FWD to lean on, no claim that has been canceled, no PTAB-construed claim term to borrow. The corollary is that there is also no estoppel binding you if you ever needed to litigate validity for some residual pre-2007 conduct. Practically, though, validity is a moot point: with no enforceable right, a § 282 invalidity defense is unnecessary. The correct first move is a § 286 / expiration-timing argument, not a prior-art argument.

Pattern signals. None available — this patent never generated a PTAB track record, so there is no serial-petitioner pattern, no defensive-aggregator activity (Unified's portal merely hosts a static patent record page for it; Unified did not file against it), and no PTAB appellate history. The absence of IPRs is not the suspicious "well-asserted patents eventually attract IPRs" signal here; it is the mundane signal of a patent that was never commercially asserted during the AIA era.

Recommended next steps

1. If you are a defendant and received a demand citing US 4,886,741: do not respond on the merits. Respond on expiration. The patent record at https://patents.google.com/patent/US4886741/en shows "Expired - Lifetime" with anticipated expiration 2007-12-09. All claims 1–12 lapsed. Cite the patent's own front-page status and the absence of any post-grant proceeding.
2. Verify the file wrapper yourself before finalizing any position. The Application Number is 07/130,709 (Patent No. 4,886,741). Pull the complete file wrapper via USPTO PatentCenter to confirm (a) the exact expiration date, (b) whether maintenance fees were ever paid and whether any lapse-and-revival occurred, and (c) whether any ex parte or inter partes reexamination certificate issued. I searched for these and found none, but file-wrapper records are the authoritative source and were not directly queryable in this session — flag this as the one open verification item.
3. Confirm the negative PTAB result directly. Query USPTO PTAB E2E and the PTAB Decisions search for patent number 4,886,741. I expect zero hits for proceedings and zero for decisions; a clean confirmation closes the file.
4. For a litigation-hold or portfolio-audit context: classify this patent as "expired / no assertion value" and stop spending on it. Its only continuing relevance is as a cited background reference in later genomics and in situ hybridization filings.
5. If the demand letter cites family members instead — e.g., WO1989005357A1 or AU29137/89A — note that these share the 1987-12-09 priority date and are equally expired. A demand resting on any member of this family fails on the same expiration ground.

If a proceeding does exist that I could not surface: I found none, and the structured ODP block is empty, but I could not fully query PTAB E2E, CourtListener's docket, or Docket Navigator in this session. If you have a proceeding number in hand, provide it and I will pull the institution decision, FWD, panel composition, and any CAFC disposition directly. I will not speculate about outcomes for a proceeding whose number I cannot verify.

I'll research the assignment chain and corporate history before writing anything.

Corporate history is emerging clearly. Let me dig further into the acquisition, the Gen-Probe dispute, and any litigation on this patent.

Now let me try to pull the actual USPTO assignment records (reel/frame) for this patent.

US 4886741 — Ownership Chain Reconstruction

Patent: US 4,886,741 A — "Use of volume exclusion agents for the enhancement of in situ hybridization"
Application: US 07/130,709 · filed 1987‑12‑09 · issued 1989‑12‑12 · expired (anticipated) 2007‑12‑09
Current assignee of record: Becton, Dickinson and Company

Verification status — read first. I could retrieve the events of this chain (from the Google Patents legal‑events record supplied and cross‑checked against corporate/SEC/press sources), but I could not retrieve reel/frame numbers, execution dates, or the recording correspondent. The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) is a JavaScript application that returns no records to a non‑browser fetch, and no mirror I reached (uspto.report, Justia, FreePatentsOnline, Unified Patents portal) exposes reel/frame for this patent. I have therefore left every reel/frame and correspondent field explicitly blank rather than guess. Do not treat the absence of reel/frame below as an absence of records — the records exist, I simply could not read the identifiers.

Inventors

Pattern notes:

• Single‑inventor patent. No co‑inventors, which is unremarkable for a process‑optimization invention (volume exclusion in hybridization buffer) as opposed to a probe‑sequence invention.
• No inventor‑departure anomaly. The "all inventors left within 12 months" fire‑sale precursor is not present. Schwartz continued to be the named inventor on MicroProbe filings well after 1987 — e.g. US 5,212,059 (filed 1990‑08‑29, issued 1993, "Oligonucleotide probes for the detection of periodontal pathogens," assignee MicroProbe Corporation) and US 5,334,501 / US 5,378,604 in the same bacterial‑probe family. Third‑party portfolio data (GoodIP) credits Schwartz with ~20 MicroProbe patents, the most of any inventor on that portfolio.
• Same‑day sibling filing. The specification incorporates by reference U.S. Ser. No. 130,754, "The Use of Ultrasound for the Enhancement of Nucleic Acid Hybridization," filed the same day (1987‑12‑09, ref. 11652‑5). Two enhancement‑method applications filed on one day signals a deliberate portfolio build around in situ assay acceleration, not a one‑off filing.

Original assignee

MicroProbe Corporation — Bothell, Washington (some records spell it "Bothel"); founded 1985; founder Martin Bak; publicly traded (ticker MPRO).

• Primary line of business: DNA/RNA probe‑based microbial identification and pathogen detection diagnostics — i.e. it practiced squarely in the field of the patent. Third‑party data show a portfolio of ~82 patent applications.
• Product embodying the claims: MicroProbe commercialized the Affirm VP line of DNA probe‑based diagnostic products. Caveat: the Affirm VP product family was an rRNA‑targeted organism‑detection assay, not an in situ hybridization on cells fixed to a glass slide. I found no evidence that MicroProbe shipped a product practicing claims 1–12 as written (fixed cells on an inert transparent support, 15–30mer probe, 1‑hour hybridization). Treat "product embodying the claims" as unclear/not established rather than confirmed.
• Distress event (relevant context): In May 1994 MicroProbe withdrew the Affirm VP product line from the market to avoid the cost of litigating a patent suit brought by Gen‑Probe Inc. (a Chugai Pharmaceutical subsidiary) in May 1993 asserting US 4,851,330 (detection/identification/quantification of non‑viral organisms by targeting ribosomal RNA). MicroProbe publicly maintained the Gen‑Probe patent was invalid over prior art.
• Status: Acquired / name retired. In 1995 MicroProbe sold its diagnostics business — including the MicroProbe name — to Becton Dickinson for $8.5 million ($3M advance, up to $1.5M contingent), a deal that also helped resolve the Gen‑Probe dispute. The shell company then renamed itself Epoch Pharmaceuticals (1995) → Epoch Biosciences (2000) → acquired by Nanogen (Dec 2004) → Nanogen acquired by Elitech Group (France, July 2009). Not a bankruptcy; a going‑concern divestiture.

Assignment timeline

Two recorded conveyances. Neither reel/frame nor execution date could be retrieved (see verification note above); recording dates are from the Google Patents legal‑events record. There is no third assignment.

1. Executed [date not retrieved] / recorded 1988-02-16 — Reel [not retrieved]/[not retrieved]

• Conveyance: Assignment
• Assignor: Dennis E. Schwartz
• Assignee: MicroProbe Corporation
• Correspondent: [not retrieved] — Assignment Center correspondent field inaccessible; not inferable from available sources. See Signal 3.
• Context: Standard employee invention assignment — sole inventor transferring rights to his employer, recorded ~2 months after the 1987‑12‑09 filing.

2. Executed [date not retrieved] / recorded 1996-01-16 — Reel [not retrieved]/[not retrieved]

• Conveyance: Assignment (asset purchase — sale of the diagnostics business)
• Assignor: MicroProbe Corporation
• Assignee: Becton, Dickinson and Company
• Correspondent: [not retrieved] — see Signal 3.
• Context: Going‑concern divestiture of a business unit, not an NPE transfer — MicroProbe Corp sold its entire diagnostics business and its corporate name to BD for $8.5M in late 1995, with the residue becoming Epoch Pharmaceuticals. Note that an instrument of this kind is normally recorded as one document covering a schedule of dozens of MicroProbe patents, so any single reel/frame for this patent almost certainly covers the whole transferred estate. (That last sentence is a reasoned expectation, not a verified fact.)

No further assignments. Nothing recorded after 1996‑01‑16 through expiry on 2007‑12‑09. BD is the assignee of record at expiration and remains the Google Patents "current assignee."

Timeline diagram

timeline
    title Ownership of US 4886741
    1987 : Filed by MicroProbe Corp
         : Sole inventor Dennis E Schwartz
    1988 : Inventor assigns rights to MicroProbe
    1989 : Patent US 4886741 issues
    1994 : Affirm VP product withdrawn
    1996 : Diagnostics business sold to Becton Dickinson
    2007 : Patent expires

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. Both assignees are operating companies. MicroProbe Corporation was a publicly traded diagnostics manufacturer (MPRO) with a commercial product line. Becton, Dickinson and Company is a Fortune 500 medtech operating company (Franklin Lakes, NJ; ~24,000 employees at FY1999 per its own 10‑K). Neither assignee is an "IP/Holdings/Licensing/Ventures" suffix entity; neither sits at a registered‑agent service address. The recorded 1996 assignee is the parent operating company, not a BD IP‑holding subsidiary — worth noting, because BD does frequently route patents through entities such as CareFusion 303, CareFusion Manufacturing, CareFusion Solutions and BD Switzerland S.à r.l. (see BD's 2025 Delaware complaints). This patent was not routed that way.

2. Known asserter in the chain — NOT PRESENT. No assignee or intermediate entity matches any public NPE list (Acacia, Marathon Patent Group, Intellectual Ventures, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). BD does not appear on Unified Patents or RPX high‑frequency‑plaintiff directories; it appears in those datasets as a defendant/target (e.g. Unified Patents records BD facing 10 oppositions per IP Verse data).

3. Repeat correspondent across the chain — UNCLEAR, NOT EVALUABLE. This is the one signal I genuinely cannot call, and I am declining to infer it. The Assignment Center correspondent field — the exact data point the prompt identifies as the most useful tell — was not retrievable for either recording here. Two things I can say precisely:

• I found no evidence of a repeat recording attorney, because I found no correspondent data at all. Absence of data is not absence of a pattern.
• Do not use this as a lead without verification: the prosecution‑side counsel of record on two sibling MicroProbe patents in the same portfolio (US 5,212,059 and US 5,334,501) is Townsend and Townsend Khourie and Crew. That is law‑firm prosecution representation on different patents, recorded in patent front pages — not the assignment correspondent on US 4,886,741, and I have no basis to assert they filed either recording. Anyone continuing this analysis should pull the actual correspondent from Reel/Frame before drawing any conclusion.

4. Cascading transfers — NOT PRESENT. Two recorded assignments across a 20‑year patent life, eight years apart, with no chained intermediaries, no common‑principal LLCs, and no clustered transfers in any 24‑month window. The classic cascade signature (three or more hops through related shells inside two years) is entirely absent.

5. Pre-litigation transfer — NOT PRESENT. I found no infringement litigation ever naming US 4,886,741, in any district, at any time. The 1996‑01‑16 assignment predates expiry by nearly 12 years with no suit following. BD's litigation activity in this space is real but concerns entirely different patents — e.g. Becton Dickinson v. Baxter, D. Del. No. 1:25‑cv‑00591 (infusion pumps, 2025) and Becton Dickinson v. NeuMoDx (molecular diagnostics, HandyLab‑derived patents). Neither implicates US 4,886,741. This matters: the 1993–94 Gen‑Probe v. MicroProbe suit over US 4,851,330 was MicroProbe being sued, not asserting this patent — the inverse of the pre‑litigation‑transfer pattern.

6. Bankruptcy fire-sale — NOT PRESENT. MicroProbe Corporation filed no Chapter 7 or Chapter 11 that I could find. The 1995 transaction was an $8.5M negotiated asset sale of a business line to a strategic buyer, structured so the residue continued as Epoch Pharmaceuticals and later reached a $1B‑scale exit via Nanogen/Elitech. Nuance worth recording: the sale was distressed in substance — the flagship product had been pulled from market 18 months earlier under patent‑litigation pressure, and the deal "helped resolve" that dispute. Distressed strategic divestiture ≠ bankruptcy fire‑sale, and the distinction matters for NPE analysis because a strategic buyer paying $8.5M for a diagnostics unit is the opposite of a shell acquiring paper.

7. Privateering — NOT PRESENT. No evidence that MicroProbe, Epoch, or BD placed this patent with a proxy asserting on its behalf. BD's consistent practice is to assert in its own name through its own operating subsidiaries (see the 2025 Baxter complaint, where BD, CareFusion 303, CareFusion Manufacturing, CareFusion Solutions and BD Switzerland are all named plaintiffs). BD is on the asserting‑operating‑company side of the table, not the privateering side.

8. Defensive aggregator — NOT PRESENT. The chain terminates at Becton, Dickinson and Company. Neither RPX, AST, LOT Network, Unified Patents, nor Open Invention Network appears anywhere in the chain. The patent was never neutralized by a defensive aggregator — it simply ran to expiry in the hands of its operating‑company owner.

Verdict

Operating-company assertion.

This is a clean two‑hop operating‑company chain: sole inventor Dennis E. Schwartz assigned to his employer MicroProbe Corporation (recorded 1988‑02‑16), which sold its diagnostics business and the patent to Becton, Dickinson and Company (recorded 1996‑01‑16) — the latter being a $8.5M going‑concern divestiture, not an NPE conveyance. Both assignees are/were product‑shipping operating companies; there are no shell LLCs, no chained intermediaries, no NPE assignee, no aggregator terminus, and zero NPE signals present on the evidence available — the only unresolved signal (repeat correspondent) is unresolved because the Assignment Center correspondent field was unreachable, not because anything suspicious was found. Two caveats the reader should carry: the "assertion" label is nominal as to this patent, since US 4,886,741 was never litigated and expired 2007‑12‑09; and BD's real assertion activity in molecular diagnostics runs through different patents and different subsidiary entities than the one named here.

Verify at: https://assignmentcenter.uspto.gov/ (search patent number 4886741) and https://assignment.uspto.gov/patent/index.html — both surface the same records; pull Reel/Frame, execution date, and correspondent for both entries to close the three blanks above. Cross‑check the legal‑events record at https://patents.google.com/patent/US4886741/en (legal events show only the 1988‑02‑16 and 1996‑01‑16 assignments, and the 2007‑12‑09 anticipated expiration).

I'll research US patent 4886741 and its prior-art citations.

Let me get the complete citation list and details on the specific prior-art references.

Let me retrieve the full patent citation list and remaining reference details.

Prior-Art Analysis — US Patent No. 4886741

0. Scope, method, and caveats (read first)

Tool limitation: In this session I had access to live web search, not a direct PDT/PatentCenter API query of the USPTO's own citation record. I therefore grounded this analysis in the patent's own front-matter/body text plus public patent databases that mirror the USPTO record:

• https://patents.google.com/patent/[US4886741A](/patent/US4886741A)/en
• https://pubchem.ncbi.nlm.nih.gov/patent/US-4886741-A
• https://portal.unifiedpatents.com/patents/patent/US-4886741-A
• https://uspto.report/patent/grant/4886741

Completeness caveat: I was not able to retrieve the complete, authoritative "References Cited" (U.S. Patent Documents) list for 4886741 in a single verified export. The databases I reached disagree slightly on the reference set, and PubChem's citation list appears partial. Below I mark each item as either (verified in the patent text/databases) or (list-only; content unverified). I have not fabricated any citation.

Literal-identifier rule honored: Patent numbers, application numbers, and dates are reproduced as they appear in the sources. Where sources conflict, I report the conflict rather than "fixing" it.

1. Identification of the patent under analysis (literal)

Because the application was filed 1987‑12‑09, this patent is governed by pre‑AIA 35 U.S.C. § 102. The critical § 102(b) statutory-bar date is therefore on or about 1986‑12‑09 (one year before filing); references published before that date are § 102(b) art, and references published between 1986‑12‑09 and the filing date are candidates under § 102(a) if "by others."

Claim 1 (independent) — the anticipation target. All of the following must appear in a single reference to anticipate:

• (a) fixing cells to an inert, transparent, solid support;
• (b) contacting the fixed cells with a hybridization mixture comprising labeled short probes of 15–30 nucleotides plus a volume exclusion agent at 2–25% (w/v);
• (c) washing excess probes, with (b)+(c) completed in ≤4 hours; and
• (d) detecting the labeled probes, correlated to the polynucleotide targets.

Independent claim 10 is the kit counterpart (fixation reagents + hybridization reagents with 15–30 nt labeled probes + 2–25% volume exclusion agent, effecting detection in ~1 hour).

2. Patent documents cited (the "Patent Citations")

2.1 U.S. Pat. No. 4,689,294 — (verified; expressly discussed in the patent text)

• Full citation: U.S. Patent 4,689,294, Boguslawski, S.J. and Deriemer, L.H., "Enhancement of hybridization of nucleic acids by anionic polymers." Application US 672,941 filed 1984‑11‑19; granted 1987‑08‑25. Family counterpart: EP 0 184 017 A2 (published 1986‑06‑11; US 4689294 A 1987‑08‑25).
• Source of the disclosure language: https://patentimages.storage.googleapis.com/31/cd/56/9119274a19f65b/US4689294.pdf
• Brief description: Discloses that the anionic polymers polyacrylate and polymethacrylate increase the rate of hybridization between complementary polynucleotide segments in aqueous medium. The acceleration is described as "particularly useful in nucleic acid hybridization assays involving immobilization of sample nucleic acids and the use of labeled probes," and the specification notes lower non-specific binding to nitrocellulose than with dextran sulfate. The reference expressly attributes earlier accelerator art to U.S. Pat. No. 4,302,204 and discusses Wetmur (1974) and Wahl et al. (1970).
• Relevance / § 102 analysis: This is the closest patent art on the volume-exclusion-agent element. The applicant's own specification concedes it and incorporates it by reference. However, it does not disclose: (i) in situ hybridization to polynucleotide targets within intact cells fixed on a transparent support (it is directed to immobilized sample nucleic acids, e.g., membrane/blot formats), (ii) probes limited to 15–30 nucleotides, or (iii) the ≤4-hour hybridization-plus-wash limitation. It therefore cannot anticipate claim 1 or claim 10 as a whole. Its only realistic anticipation exposure is to the agent-identity sub-elements recited in dependent claims 2, 3, 11 and 12 if those limitations were read in isolation — but dependent claims carry all limitations of their base claim, so no complete anticipation is available.

2.2 U.S. Pat. No. 4,302,204 — (verified; expressly discussed in the patent text)

• Full citation: U.S. Patent 4,302,204 (Wahl, G.M. and Stark, G.R.), "Hybridization method." Granted 1981‑11‑24. (Identified in the literature as the dextran-sulfate/charged-polysaccharide hybridization-acceleration patent; cf. US 4,689,294 discussion and U.S. Pat. No. 5,759,777 text.)
• Brief description: Per the 4886741 specification (Information Disclosure): "U.S. Pat. No. 4,302,204 has disclosed that the presence of volume exclusion agents may increase hybridization rates," an effect attributed to exclusion of probe molecules from the volume occupied by the agent. Related art (Wahl et al., PNAS 76:3683‑3687) describes charged polysaccharides accelerating hybridization where one polynucleotide is covalently attached to a solid phase.
• Relevance / § 102 analysis: This is the foundational "volume exclusion accelerates hybridization" reference and predates the filing by over five years — squarely § 102(b) art. But it is a solid-phase/filter hybridization teaching (immobilized nucleic acid on a support such as diazobenzyloxymethylcellulose), not in situ hybridization within fixed cells on a transparent support, and it does not restrict probes to 15–30 nt or the assay to ≤4 hours. It does not anticipate claims 1 or 10. It is material to claim 3 (dextran sulfate, 5–20%) as a disclosure of the agent, but again cannot anticipate the dependent claim standing alone.

2.3 EP 0 098 373 A2 — (list-only; content NOT verified in this session)

• Citation status: Appears in the citation list mirrored by PubChem's patent record for US‑4886741‑A (rendered there as "EP‑0098373‑A2 (SEA)").
• Full citation / dates / description: I could not retrieve or verify the bibliographic details or subject matter of EP 0 098 373 A2 in this session. I am flagging it explicitly rather than guessing. It should be pulled directly from the EPO/Espacenet record and cross-checked against the USPTO file wrapper before use.
• § 102 analysis: Cannot be assessed; treat as to be verified. (A 1983 EP publication would be § 102(b) art if it discloses any element of claims 1–12.)

2.4 WO 86/05816 A1 — (verified as cited; content characterized only as described in 4886741)

• Full citation: International (PCT) publication WO 86/05816 A1, published 1986‑10‑09 (as "WO8605816").
• Brief description (as characterized in the 4886741 specification): "discloses both a genus specific and type specific region for the HPV genome located within the L1 gene encoding the major component of the viral coat."
• Relevance / § 102 analysis: This is art directed to HPV probe-sequence selection, not to volume exclusion or in situ hybridization kinetics. It is potentially relevant to the HPV-target element of claims 4, 5 and 8 (and to the probe content of claim 10's kit). It does not disclose fixation to a transparent support, short 15–30 nt probes, volume exclusion agent, or the ≤4-hour limitation, and therefore does not anticipate claim 1, 4, 5, 8 or 10 as a whole. It is best treated as background for the HPV sub‑genus/type-specificity limitation.

2.5 Related co-pending applications cited in the specification (not third-party prior art)

• U.S. Application SN 103,979, filed 1987‑10‑02, "Human Papillomavirus Type Diagnosis With Nucleotide Probes" — incorporated by reference.
• U.S. Application SN 130,754, filed 1987‑12‑09, "The Use of Ultrasound for the Enhancement of Nucleic Acid Hybridization" (applicant's ref. file 11652‑5) — incorporated by reference.
• § 102 note: Both are same-period filings by the same assignee (MicroProbe) and appear to be commonly owned. They are related disclosures, not anticipatory prior art; their main function is enablement/support and, at most, they could be treated as § 102(e)-type art if a § 102(e) date were established, which for commonly owned applications is a routine disqualification issue under pre‑AIA § 103(c).

3. Non-patent literature cited

3.1 Amasino, R.M., "Acceleration of Nucleic Acid Rate by Polyethylene Glycol," Anal. Biochem. 152:304‑307 (1986) — (verified as cited)

• Date: 1986 (within one year of filing → at most § 102(a), and only if "by others").
• Description: Reports PEG acceleration of nucleic-acid hybridization via volume exclusion ("effective increase in probe concentration").
• § 102: Bears on the polyethylene glycol alternative in claim 2. Solution-phase rate study; no cells, no fixed transparent support, no short-probe limitation, no ≤4-hour protocol → cannot anticipate claim 1, 2, or 10.

3.2 Meinkoth, J. and Wahl, J., Anal. Biochem. 138:267‑284, at 268 (1984) — (verified as cited)

• Description: Review, "Hybridization of Nucleic Acids Immobilized on Solid Supports."
• § 102: Highly material as teach-away evidence: the article reports that as probe size decreases the dextran-sulfate enhancement diminishes, "with no effect observed for oligonucleotides of 14 bases." It supports patentability rather than anticipation — it does not anticipate any claim.

3.3 Haase, A., et al., Methods in Virology, Vol. VII, pp. 189‑226 (1984) — (verified as cited)

• Description: In situ hybridization review; reports that an average probe length of 400 nucleotides is optimal for in situ hybridization in the presence of dextran sulfate (cited at p. 205).
• § 102: Again a teach-away reference (long probes preferred). Discloses in situ hybridization generally (relevant to the "in situ in cells" context of claim 1) but not short 15–30 nt probes, not 2–25% agent with that probe length, and not the ≤4-hour limitation. Does not anticipate.

3.4 Beckmann, P.M., et al., J. Med. Virol. 16:265‑273 (1985) — (verified as cited)

• Description: "Detection and Localization of Human Papillomavirus DNA in Human Genital Condylomas by In Situ Hybridization with Biotinylated Probes." Uses long biotinylated probes with dextran sulfate.
• § 102: Closest NPL on the in situ + HPV + biotinylated-probe combination (claims 4 and 5) — but the probes are long, which is outside claim 1's "15 to 30 nucleotides." Cannot anticipate claims 1, 4 or 5 as a whole.

3.5 Milde, K. and Löning, T., J. Oral Pathol. 15:292‑296 (1986) — (verified as cited)

• Description: "Detection of Papillomavirus DNA in Oral Papillomas and Carcinomas: Application of In Situ Hybridization with Biotinylated HPV 16 Probes."
• § 102: Same posture as Beckmann — in situ HPV/biotin art with long probes; does not meet the short-probe or ≤4-hour limitations. No anticipation.

3.6 McDougall, J.K., et al., in Papillomaviruses (CIBA Foundation Symposium 120), Wiley, Chichester, pp. 86‑103 (1986) — (verified as cited)

• Description: "Methods for Diagnosing Papillomavirus Infection"; in situ localization of HPV DNA with long biotinylated probes and dextran sulfate.
• § 102: Directed to diagnoses using long probes; relevant background for claims 4, 5 and 8 (cervical/anogenital HPV detection) but does not anticipate.

3.7 Singer, R.H., et al., Biotechniques 4(3):230‑250 (1986) — (verified as cited)

• Description: "Optimization of In Situ Hybridization Using Isotopic and Non-Isotopic Detection Methods" (review).
• § 102: General in situ methodology background; no volume-exclusion/short-probe/≤4-hour teaching sufficient to anticipate.

3.8 Conner, B., et al., PNAS 80:278‑282 (1983) — (list-only in PubChem citation record; content per general knowledge, to be verified)

• Description as commonly cited: Detection of a β-globin (sickle-cell) allele using synthetic oligonucleotide probes — i.e., short-probe hybridization technology.
• § 102: Potentially bears on the "short probe" element of claim 1, but it is a solution/dot-blot oligonucleotide-screening method, not in situ hybridization in fixed cells with a volume exclusion agent; no ≤4-hour in situ protocol. No anticipation. Verify the exact pages/authors before relying on it.

3.9 Szabo, P., et al., J. Mol. Biol. 115:539‑563 (1977) — (list-only; content per general knowledge, to be verified)

• Description as commonly cited: Quantitative in situ hybridization methodology (e.g., rRNA hybridization in cytological preparations).
• § 102: In situ hybridization background only; no volume-exclusion-agent/short-probe combination. No anticipation. Verify.

3.10 Wood, W., et al., PNAS 82:1585‑1588 (1985) — (list-only; content per general knowledge, to be verified)

• Description as commonly cited: Base-composition-independent hybridization using tetramethylammonium chloride for oligonucleotide screening of gene libraries — i.e., short-oligonucleotide hybridization stringency control.
• § 102: Relevant only to short-oligonucleotide hybridization conditions; not in situ, no volume exclusion agent, no ≤4-hour protocol. No anticipation. Verify.

3.11 Additional art acknowledged in the specification (methodological background, not anticipatory)

• Gall, J.G. and Pardue, M.L. (1969), Proc. Natl. Acad. Sci. USA 63:378‑383 — formation/detection of RNA‑DNA hybrids in cytological preparations.
• John (John), Birnstiel and Jones (1969), Nature 223:582‑587 — RNA‑DNA hybrids at the cytological level.
• Hames, B.D. and Higgins, S.J. (Eds.), Nucleic Acid Hybridization: A Practical Approach, IRL Press (1987).
• Caruthers et al., Cold Spring Harbor Symp. Quant. Biol. 47:411‑418 (1982); Adams et al., J. Am. Chem. Soc. 105:661 (1983); Itakura et al., Ann. Rev. Biochem. 53:323‑356 (1984) — oligonucleotide synthesis.
• Connolly, B.A., Nucl. Acids Res. 15:3131 (1987) — linker-arm phosphoramidite chemistry (Example 3).
• Maniatis, Fritsch and Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor (1982).
• Applied Biosystems User Bulletin, Issue No. 13, Nov. 9, 1984.
• Wetmur, J.G., Biopolymers 14:2517‑2524 (1975); Wahl, Stern and Stark, PNAS 76:3683‑3687 (1979) (as cited within U.S. 4,689,294).
• These are cited in the specification as enabling/background art. None discloses the full claim 1 combination.

4. Consolidated § 102 analysis by claim

Bottom line on anticipation: None of the citations I could verify discloses every element of independent claim 1 or claim 10. The references split into two non-overlapping families — (i) hybridization-rate acceleration by volume exclusion, but in solution/solid-phase formats with long probes (U.S. 4,689,294; U.S. 4,302,204; Amasino 1986), and (ii) in situ HPV probing, but with long biotinylated probes and no volume-exclusion/short-probe/time constraints (Beckmann 1985; Milde & Löning 1986; McDougall 1986; WO 86/05816). The apparent novelty of 4886741 rests on uniting short 15–30 nt probes with volume exclusion in the in situ, fixed-cell, ≤4-hour context — the opposite of what Meinkoth & Wahl (1984) and Haase (1984) predicted for short probes. The primary § 102 exposure, if any, is partial and directed to dependent-claim sub-elements, not to the independent claims.

5. Forward citations (for context only — not prior art)

Google Patents shows 77 "Cited By" documents. These are later patents that cite 4886741 and therefore cannot anticipate it (they post-date the 1987 filing). Examples returned in the search included US5447841A (Regents of the University of California), US11447807 (fluorescent in situ sequencing), and US20060223075A1. They are useful for prosecution-history/family mapping but have zero § 102 relevance to 4886741.

6. Items requiring verification before reliance

1. EP 0 098 373 A2 — bibliographic details, publication date, and subject matter unverified; cited in a secondary database list only.
2. Complete official "References Cited" list for US 4,886,741 — the databases I reached (Google Patents, PubChem, Unified Patents, uspto.report) present inconsistent and partly truncated citation sets; the authoritative list should be taken from the USPTO PatentCenter file wrapper (https://patentcenter.uspto.gov) or the printed patent front page (column 1).
3. Conner 1983, Szabo 1977, and Wood 1985 — identified from a citation list; page/author confirmations should be checked against the originals.
4. Date discrepancies (priority 1987‑12‑08 vs 1987‑12‑09; grant 1989‑12‑11 vs 1989‑12‑12) are recorded as found and not corrected.

If you can supply the printed front-page "References Cited" facsimile (or the PatentCenter file-wrapper export), I will reconcile this list against the official record and complete the § 102 mapping, including any U.S. patents I could not verify here.

I'll ground this analysis by pulling the actual prior-art references cited on the face of US 4,886,741 (and in its Information Disclosure section), then map them onto the claims.

Now let me pull the remaining references from the patent's prior-art/Information Disclosure section (dextran sulfate solid-phase hybridization, HPV in situ detection, and the HPV probe application).

Obviousness Analysis — US 4,886,741 (Schwartz; MicroProbe Corp.; priority 1987‑12‑09)

Scope note: This is a technical § 103 analysis of the record on the face of the patent, not a legal opinion or infringement/FTO advice. Where I rely on a reference I could not retrieve in full text (notably US 4,302,204), I say so explicitly rather than paraphrasing it as if I had read it.

I. The Reference Set Actually Available

The user instruction is to work from the "Prior Art" section of the page. Two sources qualify:

(a) The "prior art keywords" index — hybridization; cells; probes; probe; volume exclusion. This is a signal of the examiner's/algorithm's art cluster: it confirms the invention was classified against an art space in which "hybridization + volume exclusion" was already a recognized pairing.

(b) The Information Disclosure section of US 4,886,741 (https://patents.google.com/patent/[US4886741A](/patent/US4886741A)/en). Condensed:

Two further references are in evidence through US 4,689,294's own IDS and therefore fairly attributable to the field: Wetmur (1975), Biopolymers 14:2517 (10 % dextran sulfate ≈ 10‑fold acceleration), Wahl et al. (1979), PNAS 76:3683 (up to 100‑fold with 10 % dextran sulfate on diazobenzyloxymethylcellulose), Renz & Kurz (1984), NAR 12:3435 (PEG superior to dextran sulfate for enzyme‑labelled probes), and Ranki et al. (1983), Curr. Top. Microbiol. Immunol. 104:307 (dextran sulfate raises non‑specific binding to nitrocellulose). (https://patentimages.storage.googleapis.com/31/cd/56/9119274a19f65b/US4689294.pdf)

II. The Claims to Be Tested

• Claim 1 — the only independent method claim: (a) fix cells to an inert, transparent, solid support; (b) contact with a hybridization mixture containing labelled short probes of 15–30 nt + a volume exclusion agent at 2–25 % (w/v); (c) wash; steps (b)+(c) ≤ 4 hours; (d) detect bound label, correlated to target detection.
• Claims 2–3 — agent is PEG or an anionic polymer (polyacrylate, polymethylacrylate, polysaccharidic); dextran sulfate at 5–20 %.
• Claims 4–8 — HPV target; biotinylated probe; probe directly conjugated to enzyme; alkaline phosphatase; cervical/anogenital samples.
• Claim 9 — glass support.
• Claim 10 — kit, requiring hybridization + wash in ≤ 4 hours, comprising fixation reagents and hybridization reagents containing 15–30 nt labelled probes + 2–25 % volume exclusion agent, the mixture effecting detectable hybridization in about 1 hour.
• Claims 11–12 — species of the agent limitation in the kit.

Note the internal tension worth flagging up front: the Summary of the Invention recites "about 15 to 50 nucleotides" and "2 % to 25 %," while the claims narrow to 15–30 nt. The 15–30 window is the only narrowing that does real work, and it is the limitation the § 103 fight will be about.

III. Ground 1 (independent claim 1): US 4,302,204 in view of Meinkoth & Wahl 1984 / Haase 1984 and Beckmann 1985 (or Milde 1986 / McDougall 1986), further in view of Singer 1986

The combination. Take Wahl '204 as the primary reference: it discloses the generic concept the claim's key limitation rests on — a volume exclusion agent (dextran sulfate and other charged polysaccharides) added to a hybridization reaction in which one polynucleotide is immobilised on a solid phase, to accelerate the reaction. Meinkoth & Wahl and Haase supply the in‑situ format (cells/tissue on a support, probe applied, wash, detect). Beckmann/Milde/McDougall supply the specific, commercially motivated application: HPV detection in clinical smears using biotinylated probes plus dextran sulfate on glass.

Motivation to combine.

1. The '741 specification itself concedes the motivation: "the need for rapid assay tests for the accurate and reproducible detection of nucleic acids has been a long standing problem. Any procedures that demonstrate a tendency to accelerate the typically multi-hour long processes are of value, especially for hybridization assays to be conducted by clinical laboratories." That is a textbook articulation of a recognized problem, supplied by the patentee.
2. The art was already combining the very elements claimed. Beckmann 1985 — cited in the '741 IDS — already performs in situ HPV detection with biotinylated probes in the presence of dextran sulfate on a solid support. The only thing arguably missing is the probe length.
3. KSR principle: "if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious." Volume exclusion had been used to accelerate solution hybridization (Wetmur), membrane/solid‑phase hybridization (Wahl '204, Wahl 1979 PNAS), filter‑bound hybridization with PEG (Amasino), and in‑situ HPV hybridisation (Beckmann). Applying it to a short‑probe in‑situ format is the same technique applied to the next‑adjacent format.

The probe-length limitation (15–30 nt). This is where the patentee's best argument lies, and it must be met head‑on:

• Meinkoth & Wahl teach that dextran‑sulfate enhancement diminishes as probe size falls, "with no effect observed for oligonucleotides of 14 bases." Haase teaches ~400 nt as optimal for in situ with dextran sulfate.
• However, (i) that teaching is at most a statement that the magnitude of enhancement shrinks — it is not a statement that an oligonucleotide in the 15–30 nt range will exhibit no enhancement; (ii) the specific data point is a 14‑mer, which sits outside the claimed range and at a length whose Tm is far below a 24‑mer's; (iii) a preference for longer probes does not rise to a teaching away absent a "criticism, disavowal, or discouragement" of the claimed alternative (In re Fulton; In re Gurley; WMS Gaming v. IGT). A reference that "merely expresses a preference" is not a teaching away.
• Independently, Singer 1986 and Haase 1984 both discuss probe size and cell entry — the smaller the probe, the better the diffusion into nucleus/cytoplasm. Given that recognised trade‑off, a POSITA seeking speed in an in‑situ format had both motivations pointing at short probes (diffusion) and at volume exclusion (kinetics). The '741 patent's own rationale — "Optimal balance between diffusion rate into the cell and hybridization specificity is achieved by using probes having between 15 and 30 bases" — is a routine optimization statement, not a discovery of an unavailable result.
• Critically, the patentee's own Table 1 consists entirely of 24‑mers, squarely inside the claimed range. The record shows the inventors regarded 24‑mers as an ordinary design selection from a known sequence region (WO 86/05816; SN 103,979), not as something made patentable by the agent.

The 2–25 % concentration range. Every sub‑range is disclosed or rendered obvious:

• Dextran sulfate 5–10 % is the art standard (Wahl '204; Wetmur; Wahl 1979; Ranki).
• Claim 3's dextran sulfate 5–20 % overlaps the art's 5–10 % and extends it; where the prior art discloses a range and the claim recites a narrower or overlapping range, the burden shifts to the applicant to show criticality (In re Peterson, 315 F.2d 817; In re Woodruff, 919 F.2d 1575; In re Geisler). No criticality data appears in the specification — Example 1 uses a single 10 % dextran sulfate condition, which is precisely the art‑standard value.
• Claim 2's PEG: Amasino discloses PEG for filter‑bound hybridization; '741 states 5–20 % PEG for MW 6–7.5 kDa, all with no data distinguishing it.
• Claim 2's polyacrylate/polymethylacrylate: US 4,689,294 expressly discloses 0.2–10 % polyacrylate and 1–50 % polymethacrylate, i.e., it brackets and overlaps the claimed 2–25 %.

The "4 hours or less" limitation. Note the drafting asymmetry: the specification's disclosure is a 7‑minute 90 °C denaturation plus 1 hour at 37 °C (Example 1) or 60 minutes at room temperature (Example 2). The 4‑hour ceiling in claim 1 is therefore not a process condition anyone would practise near — it is the result the agent produces. Under In re Kao / In re Applied Materials and the general rule that a limitation directed to a result of the combination does not confer patentability where the result follows from the known function of the combined elements, "4 hours or less" is best characterised as a recitation of the expected advantage of adding the accelerator. If the patentee argues it is a separate limitation, the response is that it is an unbounded upper limit that reads on any performance of the prior‑art in situ protocol faster than four hours, and the art's own protocols were already being shortened.

Secondary considerations — assessed cautiously. With 369+ citations to Amasino and ~979 to Meinkoth & Wahl, this was a crowded, high‑interest field; long‑felt need and the commercial success of HPV in‑situ diagnostics are available to the patentee. But (i) the nexus is weak, because Beckmann and McDougall were already performing commercial in‑situ HPV detection before the priority date; (ii) the "failure of others" argument is undercut because others were in fact succeeding with dextran sulfate and long probes — the alleged failure is simply a difference in probe length; and (iii) any unexpected‑results argument requires showing results that differ in kind or degree from what the art predicts, and the specification's own result is framed in the language of degree ("accelerated the rates or extent of hybridization as much as twentyfold") with an express disclaimer of quantification: "A precise quantitative measurement was not possible, due to the absence of a rigorous linear relationship between hybridization rates and optical density."

IV. Ground 2: US 4,689,294 in view of Amasino 1986 and Beckmann 1985 — the "different agent" route

Belt‑and‑braces alternative that does not depend on Wahl '204 (which pre‑dates the one‑year grace window and could be attacked on scope).

• US 4,689,294 supplies volume exclusion with polyacrylate/polymethylacrylate, expressly in immobilised formats and expressly covering oligonucleotide probes, with concentrations overlapping claim 1's 2–25 % (https://patents.google.com/patent/US4689294A/en).
• Amasino supplies PEG as an alternative agent for solid‑phase/support‑bound hybridization.
• Beckmann/Milde/McDougall supply the in‑situ HPV/biotinylated‑probe/glass‑slide context.
• WO 86/05816 and SN 103,979 supply the probe sequences, so selection of a 24‑mer (the '741 Table 1 length) is not inventive.
• Motivation: '294 itself states dextran sulfate's shortcomings — cost and increased non‑specific binding to nitrocellulose (Ranki) — and offers the acrylate polymers as a cheaper, equally effective substitute; '741 repeats this motivation verbatim ("Dextran sulfate … is relatively expensive"). A POSITA substituting an acrylate for dextran sulfate in Beckmann's protocol is doing exactly what '294 tells them to do.

V. Ground 3: claim 10 (the kit)

Claim 10 is a kit claim whose only substantive components are (i) fixation reagents and (ii) a hybridization reagent containing 15–30 nt labelled probes and 2–25 % volume exclusion agent.

• If claim 1 is obvious, claim 10 is obvious a fortiori where the kit contains no element beyond the reagents necessarily used to practise the claimed method. It is black‑letter that a kit claim containing the same combination of reagents as an obvious method fails with the method claim where the packaging/instruction content adds nothing.
• Each component is separately known: fixation reagents (ethanol, Carnot's B — '741's own list; standard in the art), glass slides and collection spatulas (routine clinical consumables; Ayer's spatula), short biotinylated HPV probes (Beckmann; Milde; WO 86/05816; SN 103,979), dextran sulfate (Wahl '204), enzyme‑substrate detection reagents (NBT/BCIP; avidin‑alkaline phosphatase conjugates).
• The "hybridization period of about 1 hour" in claim 10 is not a different invention from Example 2's "hybridize at room temperature for 60 minutes" — it is that Example, restated as a kit property. A kit cannot be rendered non‑obvious by reciting the performance characteristic of the protocol its reagents are designed to run.
• The patentee's strongest kit‑specific point is the combination‑of‑reagents argument (a kit is a physically packaged article). But the '741 kit adds no reagent with a function not already performed in the prior‑art assay; the "assembly" is the ordinary commercial packaging of an obvious assay.

VI. Claim‑by‑Claim Mapping

VII. Anticipating the Patentee's Rebuttals

1. "The art teaches away — Meinkoth & Wahl says no effect for 14‑mers, Haase says 400 nt is optimal." Strongest argument, but incomplete. A teaching away requires the reference to "criticize, disavow, or discourage" the claimed route (In re Fulton). Meinkoth & Wahl reports an absence of measurable effect at a single length below the claim; it does not say a 24‑mer will not be accelerated, and it is expressly framed as a size‑dependence trend, not a prohibition. Haase's 400 nt figure is an optimisation for a dextran‑sulfate/isotopic protocol, not a statement that shorter probes fail. Moreover, both references simultaneously teach that short probes penetrate cells better — supplying the opposite motivation.

2. "Unexpected results — twenty‑fold acceleration with short probes." The specification's own quantification is hedged ("a precise quantitative measurement was not possible"), and the 20‑fold figure is anchored to 10 % dextran sulfate — the very condition disclosed by Wahl '204/Wetmur as giving ~10‑ to 100‑fold acceleration. That is a difference in degree along a continuum the art already reported, which is the classic case for rejecting an unexpected‑results argument absent a showing of a genuinely new property.

3. "Long‑felt need / failure of others." Weakened by the fact that the same clinical problem was being solved with long biotinylated probes plus dextran sulfate pre‑priority (Beckmann 1985; Milde 1986; McDougall 1986). The "need" was not unmet — it was being met by a longer probe, which is why the 15–30 nt limitation is a design choice rather than a solution to failure.

4. "Criticality of the 2–25 % / 5–20 % ranges." No data in the specification establishes criticality; Example 1 uses 10 % and Example 3 uses 5 %, both squarely within the art's disclosed operating windows for dextran sulfate.

VIII. Overall Assessment and Residual Uncertainty

On this record, all twelve claims are vulnerable under § 103. The strongest prima facie case is the Wahl '204 + Meinkoth & Wahl / Haase + Beckmann + WO 86/05816 combination with Amasino and US 4,689,294 as alternative-agent references and Singer 1986 for the short-probe diffusion motivation. An alternative, Wahl‑independent case runs through US 4,689,294 + Amasino + Beckmann.

The weakest link in the case — and the point on which the patentee would win if anything survives — is the 15–30 nt limitation combined with the art's express statements that volume exclusion works best with long probes. If the patentee can adduce comparative data (in the specification or, on a Rule 132 declaration, later) showing a genuinely unexpected kinetic regime for 15–30 nt probes — for example, that the enhancement is disproportionately large, or that the shorter probe is required to reach the intracellular target at all — that could rebut. On the face of the patent as issued, no such data is present, and the specification affirmatively concedes the uncertainty of its own twenty‑fold figure.

Two caveats I want to state plainly:

• I could not retrieve the full text of US 4,302,204. I have characterised it from the '741 IDS and from the description in US 5,853,986, which confirms Wahl '204 is understood in the field to address volume exclusion (dextran sulfate and charged polysaccharides) for solid‑phase and in‑situ hybridization. A full-text check of '204's examples and claims would be needed to confirm whether it reaches in‑situ as opposed to membrane‑based formats.
• US 4,689,294 issued 25 Aug 1987, less than one year before the 9 Dec 1987 filing. It is therefore not § 102(b) art by its grant date, but its underlying application filing date would make it available under pre‑AIA § 102(e)/(a). Its status as prior art should be verified by checking its filing date, and by confirming there is no common ownership with the '741 application that would trigger § 103(c).

Sources consulted: US 4,886,741 (https://patents.google.com/patent/US4886741A/en); US 4,689,294 (https://patents.google.com/patent/US4689294A/en and https://patentimages.storage.googleapis.com/31/cd/56/9119274a19f65b/US4689294.pdf); Amasino 1986 (https://pubmed.ncbi.nlm.nih.gov/2421601/); Meinkoth & Wahl 1984 (https://pubmed.ncbi.nlm.nih.gov/6204550/); US 5,853,986 as evidence of how the field read US 4,302,204 (https://patentimages.storage.googleapis.com/82/7e/8c/95afd27ffe82dc/US5853986.pdf).